Urotensin II (U-II) is a disulfide bridged peptide hormone identified as the ligand of a G protein-coupled receptor. Human U-II (H-Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) has been described as the most potent vasoconstrictor compound identified to date. We have previously identified the compound termed urantide (H-Asp-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH), which is the most potent UT receptor (UTR) antagonist described to date. Urantide may have potential clinical value in the treatment of atherosclerosis. In the present study, we studied the conformational preferences of urantide in DPC micelles and developed a urantide/UTR interaction model. This model can help the design of novel peptides and small molecules as UTR antagonists.

Urantide Conformation and Interaction with the Urotensin-II Receptor / Brancaccio, Diego; Limatola, Antonio; Pietro, Campiglia; GOMEZ MONTERREY, ISABEL MARIA; Novellino, Ettore; Grieco, Paolo; Carotenuto, Alfonso. - In: ARCHIV DER PHARMAZIE. - ISSN 0365-6233. - 347:(2014), pp. 185-192. [10.1002/ardp.201300269]

Urantide Conformation and Interaction with the Urotensin-II Receptor

BRANCACCIO, DIEGO
Primo
;
LIMATOLA, ANTONIO;GOMEZ MONTERREY, ISABEL MARIA;NOVELLINO, ETTORE;GRIECO, PAOLO;CAROTENUTO, ALFONSO
2014

Abstract

Urotensin II (U-II) is a disulfide bridged peptide hormone identified as the ligand of a G protein-coupled receptor. Human U-II (H-Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) has been described as the most potent vasoconstrictor compound identified to date. We have previously identified the compound termed urantide (H-Asp-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH), which is the most potent UT receptor (UTR) antagonist described to date. Urantide may have potential clinical value in the treatment of atherosclerosis. In the present study, we studied the conformational preferences of urantide in DPC micelles and developed a urantide/UTR interaction model. This model can help the design of novel peptides and small molecules as UTR antagonists.
2014
Urantide Conformation and Interaction with the Urotensin-II Receptor / Brancaccio, Diego; Limatola, Antonio; Pietro, Campiglia; GOMEZ MONTERREY, ISABEL MARIA; Novellino, Ettore; Grieco, Paolo; Carotenuto, Alfonso. - In: ARCHIV DER PHARMAZIE. - ISSN 0365-6233. - 347:(2014), pp. 185-192. [10.1002/ardp.201300269]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/585481
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact